SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Gene J. Abel who wrote (653)4/29/1997 2:42:00 PM
From: tommysdad   of 6136
 
Who knows if it is good or bad, but it is curious. Agouron's claim
to fame is "rational drug design", that is, the design of drugs based
on X-ray crystal structural information/computer modelling. A high-powered rifle shot, aimed very carefully, if you will. Now they've bought a combinatorial chemistry company, designed to make thousands or even millions of compounds at random, i.e., the shotgun approach.
Do they have the capability to screen that many compounds? For what targets? Are they abandoning rational drug design? Anybody know?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News